Journal article

Measurement of Human Papillomavirus-Specific Antibodies Using a Pseudovirion-Based ELISA Method

Zheng Quan Toh, Laura He, Catherine Chen, Angela Huang, Fiona M Russell, Suzanne M Garland, Rita Reyburn, Tupou Ratu, Evelyn Tuivaga, Ian H Frazer, E Kim Mulholland, Paul V Licciardi

Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2020

Abstract

Human papillomavirus (HPV) vaccines are safe and effective in preventing HPV infection and cervical precancers. Neutralizing antibodies are thought to be the primary mechanism of protection for HPV vaccines, although the exact level required for protection has not been identified. Three common serological assays used in clinical trials to measure HPV antibodies are HPV pseudovirion-based neutralization assay (PBNA), competitive or total Luminex immunoassays (cLIA or LIA) and VLP-based enzyme linked immunosorbent assays (ELISA). While PBNA is the gold-standard for measuring neutralizing antibodies (NAb), it is labor intensive. Luminex immunoassay and VLP-ELISA are rapid and high throughput, b..

View full abstract

Grants

Funding Acknowledgements

This work was supported by the Department of Foreign Affairs and Trade of the Australian government and the Fiji Health Sector Support Program (FHSSP). FHSSP is implemented by ABT Associates on behalf of the Australian government. PL is supported by an Australian National Health and Medical Research Council (NHMRC) Career Development Fellowship. FR, SG and IF are supported by NHMRC Leadership Fellowships. This work was also supported in part by the Victorian government's Operational Infrastructure Support Program. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.